Project Grant R03CA313243
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $154K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Augusta, GA 30912, USA
Similar Awards
- Federal Grant Award Summary Duke University's Office of Research Administration received a $693,403 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on June 9, 2026, with an ultimate completion date of May 31, 2031. This award supports research to identify and inhibit novel downstream effectors of mutant RAS (specifically KRAS) for targeted cancer treatment. The project addresses a critical gap in cancer therapeutics by developing...
- Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $411,152 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 5, 2025, with completion targeted for August 31, 2027. This research initiative focuses on identifying and validating noncovalent protein interactions of mutant KRAS (MKRAS) inhibitors, addressing a critical gap in understanding off-target effects of recently FDA-approved...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $682,673 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) for research on "Adaptation and Evolution of Resistance to Pan-RAS Inhibition in Pancreatic Ductal Adenocarcinoma." The award period runs from May 1, 2026, through April 30, 2031. This research builds upon preclinical findings...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $675,009 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2026 through July 31, 2031. This five-year research initiative focuses on the development of covalent inhibitors targeting RAS Q61 mutations in cancer, specifically addressing K-RASQ61X and N-RASQ61X oncoproteins that comprise nearly 90% of RAS Q61...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $131,727 to The University of Texas Southwestern Medical Center (award date: May 7, 2026; completion date: April 30, 2029) under the Cancer Research Manpower program (CFDA 93.398). This grant supports biomedical research training and workforce development focused on characterizing a novel covalent RAS dimer mechanism in RASQ61 mutant-driven cancers. The research aims to develop therapeutic strategies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Project Grant Award Summary The University of Pittsburgh received a $1.3M project grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, through May 31, 2030. The award funds development of highly tumor-selective pan RAS inactivators targeting oncogenic RAS-driven cancers. The project addresses a critical unmet medical need: RAS mutations occur in 46% of all human cancers and drive resistance to existing...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...